Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072161 · ClinicalTrials.gov registry record · Phase 2
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
A Phase 2 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT02072161 is a Phase 2 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 133 participants.
The verdict
NCT02072161, a Phase 2 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.
Interventions
- DRUG Placebo
- DRUG ETC-1002
- DRUG Statin Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02072161
The ClinicalTrials.gov registry entry for NCT02072161 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02072161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02072161 about?
NCT02072161 is a clinical study titled "Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy". The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.
What is the current status of trial NCT02072161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2014-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02072161?
The interventions under investigation include: Placebo (DRUG), ETC-1002 (DRUG), Statin Therapy (DRUG).
Who is sponsoring clinical trial NCT02072161?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.